ERBB2 and breast cancer: Notably, among HER2+ BC patients (n=46) who received docetaxel, anthracycline and CTX, the use of antibiotics (n=19 vs n=23 patients in the control group) was significantly associated with lower efficacy of the neoadjuvant therapy and worse DFS and OS (72).